Expression changes of Tim-3 as one of supplementary indicators for monitoring prognosis of liver pathological changes in chronic HBV infection

• Published in: BMC infectious diseases 2022-11, Vol.22 (1), p.1-842, Article 842
• Main Authors: Wu, Shanshan, Du, Xinfang, Lou, Guohua, Yu, Shuihong, Lai, Kecong, Qi, Jinjin, Ni, Shujun, Chen, Zhi, Chen, Feng
• Format: Article
• Language: English
• Subjects: Antibodies; Antigens; Antiviral agents; Biopsy; Care and treatment; Chronic hepatitis B; Chronic infection; Development and progression; Fibrosis; Follow-up; Health aspects; Hepatitis B; Hepatitis B e antigen; Immunity; Immunoglobulins; Indicators; Infections; Infectious diseases; Inflammation; Laboratories; Liver; Liver biopsy; Liver cancer; Liver diseases; Monitoring; Pathology; Patients; Prognosis; Remission (Medicine); Risk factors; Serology; Signal transduction; Statistical analysis; T-cell immunoglobulin and mucin domain containing molecule 3; Telemedicine; Therapy; Tissues
• ISSN: 1471-2334; 1471-2334
• DOI: 10.1186/s12879-022-07841-1

This study was designed to analyze the liver tissue changes among the CHB patients who received treatment for at least 6 months and follow-up for at least 1 year, together with the correlation between the different disease condition and serum markers. One-hundred and eighty-five CHB patients underwent antiviral therapy for at least 6 months were enrolled. In the 12-month follow-up, ultrasonography-guided biopsy was performed. The patients were grouped based on the serum markers and pathological changes in liver tissues. Then we determined the serum markers, virological tests and Tim-3 expression among these groups. Antiviral therapy significantly reduced liver inflammation indicators and serum Tim-3 level. However, the fibrosis process of liver tissue was not changed, and there are still disputes on the serum marker and hepatic lesion outcomes. Under normal liver function or negative hepatitis B e antigen (HBeAg) of CHB patients, there might be consensus between Tim-3 change and liver pathological outcome. According to the liver tissue inflammation and fibrosis conditions, Tim-3 was positively correlated with liver function indices. Besides, it was also related to fibrosis stage and inflammation grade. There were inconsistent changes between serum markers and liver tissue conditions after anti-viral therapy. Tim-3 expression was more suitable to indicate the changes of liver inflammatory and fibrosis response to some extent than ALT and AST. It may serve as a certain indicator to predict the CHB prognosis, which could be used as one of the monitoring indicators in liver pathological changes of chronic HBV infection, especially in monitoring liver tissue inflammation.